Uri Geiger

Uri Geiger

Uri Geiger brings extensive entrepreneurial, management and investment know-how, having created and built many successful medical device enterprises. Until January 2009, Dr. Geiger served as CEO of Exalenz Bioscience Ltd. (TASE:EXEN), developer of an innovative breath-based technology for diagnosing liver and gastrointestinal disorders that was acquired from Oridion Systems (today part of Covidien) and Dr. Geiger took public in 2007. He previously co-founded and was the CEO of GalayOr Networks, a developer of optical components, sold in 2003 to MEMSCAP (EuroNext: MEMS). Dr. Geiger is also the founding partner of Dragon Variation Fund, one of Israel’s first hedge funds, which was sold to Migdal in 2007. Dr. Geiger worked on Wall Street during the 1990s, where he gained a broad understanding of capital markets and significant experience, which he put to use after returning to Israel in 1999. Dr. Geiger was formerly an adjunct professor at the Recanati Business School at Tel Aviv University, where he lectured on private equity and venture capital. He is the author of the books: Startup Companies and Venture Capital (Tel Aviv University Press, 2001) and From Concept to Wall Street (Financial Times – Prentice Hall, 2003). He earned his doctorate from New York’s Columbia University Center for Law & Economics, where he majored in global equity markets. Dr. Geiger served as a major in the Israeli Air Force.